JHVEPhoto/iStock Editorial via Getty Images A phase 3 study found that a subcutaneous version of Johnson & Johnson's Tremfya (guselkumab) was effective in treating Crohn's disease. Data from the GRAVITI study showed that the SC version of the IL-23 inhibitor led to significant clinical remission.
Back to Health Page
